Leaderboards/Chemotherapy-related skin toxicity

Chemotherapy-related skin toxicity

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Fabrizio Martora
Federico II University Hospital
2
Muhammad Shahid Latif
Gomal University
3
Akhil Santhosh
All India Institute of Medical Sciences
4
Jason Yerke
Cleveland Clinic
5
Paulina Słonimska
Gdańsk University of Technology
6
Shara Francesca Rapa
University of Salerno
7
Siri A. Eikeland
Oslo University Hospital
8
Kevin Sheng-Kai
Massachusetts General Hospital
9
Robert Knoerl
University of Michigan
10
Mashiro Okunaka
National Cancer Center Hospital East

Rising Stars Papers

1
Chemotherapy-Mediated Complications of Wound Healing: An Understudied Side Effect
Advances in Wound Care|2024
49 cit.
2
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
Clinical Cosmetic and Investigational Dermatology|2024
40 cit.
3
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial
Journal of Clinical Oncology|2024
37 cit.
4
Exploring Chemotherapy-Induced Peripheral Neuropathy Management Practice Patterns Among Oncology Clinicians
Seminars in Oncology Nursing|2024
13 cit.
5
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
Journal of Dermatological Treatment|2024
10 cit.
6
Association of Chemotherapy-Induced Peripheral Neuropathy with Diet Quality Among Post-Treatment Cancer Survivors
Nutrition and Cancer|2024
9 cit.
7
Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study
Therapeutic Advances in Medical Oncology|2024
8 cit.
8
Exploring clinical markers of Axon degeneration processes in Chemotherapy-induced peripheral neuropathy among young adults receiving vincristine or paclitaxel
BMC Neurology|2024
6 cit.
9
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient
Dermatology and Therapy|2025
5 cit.
10
Exploring Adolescent and Young Adult Cancer Survivors’ Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews
Journal of Adolescent and Young Adult Oncology|2024
4 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Annamaria Mancuso
Europa Donna
2
Jonathan S. Leventhal
Yale University
3
Claudio Marasca
Ospedale Antonio Cardarelli
4
Ruth Cassidy
University of Michigan
5
Young Ju Cheon
University of Seoul
6
Andrew Strunk
Northwell Health
7
Sepideh Elyasi
Tehran University of Medical Sciences
8
Andréa Machado Coelho Ramos
Universidade Federal de Minas Gerais
9
Chengliang Zhang
Tongji Hospital
10
Xiuhua Ren
Tongji Hospital

Emerging Leaders Papers

1
Ginsenoside Rg1 alleviates ANIT-induced cholestatic liver injury by inhibiting hepatic inflammation and oxidative stress via SIRT1 activation
Journal of Ethnopharmacology|2023
48 cit.
2
Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
JAAD Case Reports|2022
39 cit.
3
A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?
Skin Appendage Disorders|2022
32 cit.
4
Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use
JAMA Dermatology|2022
13 cit.
5
Knowledge, Practices, and Perceived Barriers in Cancer Pain Management at Oncology Units: A Cross-Sectional Survey of Medical Staff in China
DOAJ (DOAJ: Directory of Open Access Journals)|2022
12 cit.
6
Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa
British Journal of Dermatology|2023
12 cit.
7
Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa
JAMA Dermatology|2025
10 cit.
8
Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical
DARU Journal of Pharmaceutical Sciences|2022
8 cit.
9
Evaluation of a new herbal formulation (Viabet®) efficacy in patients with type 2 diabetes as an adjuvant to metformin: A randomized, triple-blind, placebo-controlled clinical trial
Journal of Herbal Medicine|2022
8 cit.
10
Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression
Journal of Clinical and Translational Hepatology|2023
8 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Mario E. Lacouture
Garden City Community College
2
Mary Alexander
Regenstrief Institute
3
Anthony J. Viera
University of North Carolina at Chapel Hill
4
Scott M. Lippman
UC San Diego Health System
5
Robert S. Benjamin
The University of Texas MD Anderson Cancer Center
6
Steven A. Rosenberg
National Cancer Institute
7
Janice P. Dutcher
Lung Cancer Research Foundation
8
Gregor B. E. Jemec
Gentofte Hospital
9
Jun J. Mao
Memorial Sloan Kettering Cancer Center
10
Elisabeth Paietta
Montefiore Medical Center

Current Senior Leaders Papers

1
Understanding interobserver agreement: the kappa statistic.
PubMed|2005
7.1k cit.
2
Cancer immunotherapy: moving beyond current vaccines
Nature Medicine|2004
3k cit.
3
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Science|2002
2.8k cit.
4
A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
New England Journal of Medicine|1987
2.8k cit.
5
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
New England Journal of Medicine|2003
2.7k cit.
6
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
New England Journal of Medicine|1985
2.6k cit.
7
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Science|2006
2.6k cit.
8
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Molecular Therapy|2010
2.5k cit.
9
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
New England Journal of Medicine|1988
2.3k cit.
10
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
The Journal of Experimental Medicine|1982
2.2k cit.

Reagents for Chemotherapy-related skin toxicity

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 64

RUNX2 (D1L7F) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

#71042$465
View Evidence →
Cell Signaling TechnologyEvidence 61

Phospho-FoxM1 (Ser35) Antibody

#14170$362
View Evidence →